Division of Cardiology, Thomas Jefferson University Hospital, 833 Chestnut Street, Suite 630, Philadelphia, PA, 19107, USA.
Department of Medicine, Thomas Jefferson University Hospital, 833 Chestnut Street, Suite 630, Philadelphia, PA, 19107, USA.
Curr Cardiol Rep. 2024 Sep;26(9):995-1003. doi: 10.1007/s11886-024-02101-x. Epub 2024 Aug 2.
Heart failure is a clinical syndrome with signs and symptoms from underlying cardiac abnormality and evidence of pulmonary or systemic congestion on laboratory testing or other objective findings (Bozkurt et al. in Eur J Heart Fail 23:352-380, 2021). Heart failure with reduced ejection fraction (HFrEF), when heart failure is due to underlying reduction in ejection fraction to 40. The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications.
Use of medications from each class as recommended in the 2022 Guidelines can provide significant morbidity and mortality benefits for our patients. Despite advances in therapeutics for patients with HFrEF, patients are frequently under treated and more research is needed to help optimize management of these complicated patients.
心力衰竭是一种临床综合征，具有基础心脏异常的体征和症状，并在实验室检查或其他客观发现中显示出肺部或全身充血的证据（Bozkurt 等人，在 Eur J Heart Fail 23:352-380, 2021）。射血分数降低的心力衰竭（HFrEF），当心力衰竭是由于基础射血分数降低至 40% 引起的。本综述的目的是简要描述 2022 年 AHA/ACC/HFSA 指南中描述的各种药物干预措施的机制和益处，重点关注 C 期：有症状的 HFrEF 心力衰竭，同时为这些药物的安全使用提供基本指导。
按照 2022 年指南的建议使用每类药物都可以为我们的患者提供显著的发病率和死亡率益处。尽管 HFrEF 患者的治疗取得了进展，但患者经常治疗不足，需要更多的研究来帮助优化这些复杂患者的管理。
